| Title |
Avelumab: First Global Approval
|
|---|---|
| Published in |
Drugs, April 2017
|
| DOI | 10.1007/s40265-017-0749-6 |
| Pubmed ID | |
| Authors |
Esther S. Kim |
| Abstract |
Avelumab (Bavencio(®)) is an intravenously administered programmed cell death ligand-1-blocking human antibody initially developed by EMD Serono Inc. (the biopharmaceutical division of Merck KGaA, Darmstadt, Germany) [now jointly developed and commercialized by EMD Serono Inc. and Pfizer] for the treatment of various tumours. It has received accelerated approval in the USA for the treatment of metastatic Merkel cell carcinoma (mMCC) in adults and paediatric patients aged ≥12 years. The marketing authorization application for avelumab in the treatment of mMCC is undergoing regulatory review in the EU, the biologics license application for avelumab in the treatment of urothelial carcinoma is undergoing priority review by the FDA, and avelumab is in various stages of development internationally for a variety of cancers. This article summarizes the milestones in the development of avelumab leading to this first approval for mMCC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Comoros | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 77 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 23% |
| Student > Master | 11 | 14% |
| Student > Bachelor | 9 | 12% |
| Student > Ph. D. Student | 8 | 10% |
| Student > Doctoral Student | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 20 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 19% |
| Biochemistry, Genetics and Molecular Biology | 11 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Chemistry | 8 | 10% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 4 | 5% |
| Unknown | 27 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2021.
All research outputs
#6,475,974
of 22,968,808 outputs
Outputs from Drugs
#1,117
of 3,283 outputs
Outputs of similar age
#103,461
of 310,964 outputs
Outputs of similar age from Drugs
#17
of 42 outputs
Altmetric has tracked 22,968,808 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,964 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.